Amesite Inc.

Day range

$0.61 – $0.64

Open

$0.64

Prev close

$0.62

Volume

17.56K

Market cap

$4.04M

Shares out

6.55M

P/E

—

P/S

11.13

P/B

1.53

P/FCF

—

ROE

-116.7%

ROA

-102.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationSep 11, 2026

  Amesite Inc. ... has prepared presentation materials (the "Presentation Materials") that management intends to use from time to time in presentations about the Company's operations and performance, including at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14, 2026, through September 16, 2026. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.

• Public offeringJul 20, 2026

  On July 17, 2026, Amesite Inc. (the "Company"), entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC as agent (the "Agent"), pursuant to which the Company may offer and sell, from time to time through the Agent, shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to the Maximum Amount.

• Annual meeting resultsJul 13, 2026

  On July 13, 2026, the Company held its annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders considered and approved four proposals... Set forth below are the final voting results for each of the proposals.

• Significant contract awardMay 19, 2026

  Amesite Inc. issued a press release announcing that it has secured a new enterprise customer representing an approximately 2,700-patient census—its largest deployment to date and a major milestone in validating its enterprise strategy.

• Private placementApr 28, 2026

  In a concurrent private placement (the "Private Placement" and, together with the Registered Direct, the "Offerings"), the Company entered into a securities purchase agreement (the "PIPE Purchase Agreement" and together with the RD Purchase Agreement, the "Purchase Agreements") with certain institutional investors, pursuant to which the Company agreed to issue and sell to such investors, (i) pre-funded warrants (the "Pre-Funded Warrants") to purchase 696,866 shares of Common Stock, (ii) Series A-1 warrants (the "Series A-1 Warrants") to purchase an aggregate of 1,393,732 shares of Common Stock and (iii) Series A-2 warrants (the "Series A-2 Warrants") to purchase an aggregate of 1,393,732 shares of Common Stock at a combined purchase price of $1.434 per Pre-Funded Warrant and accompanying Common Warrants.

Days to cover

1.0

Short interest

50.03K

Avg volume

198.55K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Amesite’s NurseMagic™ Wins 2,700-Census Home Care Enterprise Customer
  positiveGlobeNewswire Inc.· May 18, 2026
• Amesite Announces Closing of Up To $7.8 Million Concurrent Registered Direct Offering and Private Placements Priced At-the-Market Under Nasdaq Rules
  neutralGlobeNewswire Inc.· Apr 28, 2026
• New Advances in Healthcare AI Could Unlock Billions in Market Opportunity
  positiveBenzinga· Apr 29, 2025
• New Advances in Healthcare AI Could Unlock Billions in Market Opportunity
  positiveBenzinga· Apr 29, 2025
• Amesite (Nasdaq: AMST) Anticipates Sales Growth Amid Shifting Trade Dynamics
  positiveGlobeNewswire Inc.· Apr 4, 2025